BrainStorm Cell Therapeutics

WallStreet Research initiates coverage of BrainStorm Cell Therapeutics' shares

Published in Lab Business Week, April 30th, 2006

BrainStorm Cell Therapeutics (BCLI), the developer of NurOwn bone marrow-derived stem cell therapeutic products for the treatment of neurodegenerative diseases, announced that WallStreet Research (WSR) has initiated its analyst research coverage of the company's shares.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn, based on autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn patent pending technology is based on discoveries made by the team of neurologist, Eldad Melamed, head of neurology at Rabin Medical Center, and ecell biologist Daniel Offen at the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-04-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry